Pharmaceutical Technology: A tough puzzle: complexity slows drug development for concussions

Written By Holly Plante

Condition heterogeneity warrants multiple therapeutic approaches, but past failures highlight developmental challenges.

Adam Zamecnik September 12, 2022

Holly Plante
Previous

ACRM Conference Presentation: The injection of Ghrelin (OXE-103) improves subacute concussion symptom burden and quality of life
Next

Roll Call: We need more than brain injury awareness: We need new treatment